Morgan Stanley analyst Terence Flynn raised the firm’s price target on Eli Lilly (LLY) to $1,171 from $1,090 and keeps an Overweight rating on the shares. Following the recently announced GLP-1 pricing and access agreements between the Trump administration, Lilly and Novo (NVO), the firm says its Medicare obesity sensitivity analysis provides its with “additional confidence in our above consensus LLY estimates.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Mangoceuticals partner with Eli Lilly, Novo, provide access to Zepbound, Wegovy
- Citigroup Sees 50% Upside in Eli Lilly Stock (LLY)
- Closing Bell Movers: Cisco jumps 7% to record highs after beat-and-raise
- Eli Lilly initiated with an Outperform at Scotiabank
- Eli Lilly price target raised to $1,500 from $1,250 at Citi